Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CC-1 + VAC-XS15-PC01 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CC-1 | CC1|CC 1 | CD3 Antibody 128 PSMA Antibody 25 | CC-1 is a bispecific antibody that targets both prostate specific membrane antigen (PSMA) and CD3, potentially resulting in antitumor activity (Cancer Res 2022;82(12_Suppl):Abstract nr CT141). | |
| VAC-XS15-PC01 | Limited information is currently available on VAC-XS15-PC01, a putative prostate cancer-specific multi-peptide vaccine (Oct 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07860047 | Phase II | CC-1 + VAC-XS15-PC01 VAC-XS15-PC01 CC-1 | Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer (ImmProCure) | Recruiting | DEU | 0 |